CN118388609B - A stable protective agent for low-concentration enzyme-labeled streptococcal protein G - Google Patents
A stable protective agent for low-concentration enzyme-labeled streptococcal protein G Download PDFInfo
- Publication number
- CN118388609B CN118388609B CN202410496155.2A CN202410496155A CN118388609B CN 118388609 B CN118388609 B CN 118388609B CN 202410496155 A CN202410496155 A CN 202410496155A CN 118388609 B CN118388609 B CN 118388609B
- Authority
- CN
- China
- Prior art keywords
- enzyme
- labeled
- protein
- buffer solution
- tris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物检测领域，具体公开了一种低浓度酶标记链球菌蛋白G的稳定保护剂，为了解决低浓度下酶标记链球菌蛋白G的稳定性较差的问题，由以下原料组成：0.1‑0.5%的鱼明胶、0.1%‑0.5%的鸡卵清白蛋白、0.5%的聚乙烯吡咯烷酮、0.5%的三乙醇胺、0.2%的甘油、0.02%的吐温20、0.1%的Proclin300。本发明采用惰性蛋白与高分子聚合物、多羟基化合物，可长时间维持酶标记链球菌蛋白G在低浓度液体状态下的结构和活性稳定；采用新型杀菌防腐剂抑制体系，可有效防止微生物滋生，安全环保，有效延长保存期；采用惰性保护蛋白，避免对酶标记链球菌蛋白G的干扰。
The present invention relates to the field of biological detection, and specifically discloses a stable protective agent for low-concentration enzyme-labeled streptococcal protein G. In order to solve the problem of poor stability of enzyme-labeled streptococcal protein G at low concentration, the protective agent is composed of the following raw materials: 0.1-0.5% fish gelatin, 0.1%-0.5% chicken egg white albumin, 0.5% polyvinyl pyrrolidone, 0.5% triethanolamine, 0.2% glycerol, 0.02% Tween 20, and 0.1% Proclin 300. The present invention adopts inert protein, high molecular polymer, and polyhydroxy compound, and can maintain the structure and activity stability of enzyme-labeled streptococcal protein G in a low-concentration liquid state for a long time; adopts a new bactericidal preservative inhibition system, can effectively prevent microbial growth, is safe and environmentally friendly, and effectively prolongs the shelf life; adopts inert protective protein to avoid interference with enzyme-labeled streptococcal protein G.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to a stable protective agent for low-concentration enzyme-labeled streptococcus protein G.
Background
The enzyme-linked immunosorbent assay (ELISA) is an immunodiagnosis technology established by using an enzyme-labeled complex as a secondary antibody, has the characteristics of simple operation, quick reaction, capability of detecting a plurality of samples with high flux and the like, and is widely applied to a plurality of fields such as biology, medicine and the like. The enzyme-labeled complex is used as one of key components in ELISA kits, and the stability of the enzyme-labeled complex is also a key index for measuring the quality of the kit products. The enzyme-labeled complex is used as a protein, and needs to be stored under low temperature conditions, so that in general, the stock solution of the enzyme-labeled complex needs to be stored at-20 ℃ and below, but in an ELISA kit, the enzyme-labeled complex needs to be diluted by more than thousands of times and stored at 2-8 ℃ together with the ELISA kit, at this time, the enzyme-labeled complex with low concentration is unstable and easy to degrade and lose biological activity, so that it is highly desirable to provide a stable protective agent for the enzyme-labeled complex with low concentration, so that the enzyme-labeled complex can be stored at 2-8 ℃ and has stable properties and no obvious reduction of biological activity.
Streptococcal protein G (G protein for short) is a streptococcal cell wall protein capable of combining with various mammal antibodies IgG, and is applied to the detection field of various mammal antibodies instead of secondary antibodies due to strong binding force and wide binding spectrum. The prior invention patent CN115993460A relates to the research of alkaline phosphatase-marked myoglobin antibody diluent, CN109900900A relates to alkaline phosphatase-marked procalcitonin antigen or antibody diluent and the like, but until the present, no patent report related to enzyme-marked streptococcal protein G stabilizing and protecting agent exists, and in view of the unique biological characteristics of the enzyme-marked streptococcal protein G and the wide application prospect of the detection kit, the stability of the enzyme-marked streptococcal protein G under low concentration needs to be further improved and promoted.
Disclosure of Invention
The invention aims to solve the defects in the prior art, and provides a stabilizing and protecting agent for low-concentration enzyme-labeled streptococcus protein G, which can effectively protect the enzyme-labeled streptococcus protein G with working concentration from being still stable at 2-8 ℃ for 12 months, and the biological activity of the enzyme-labeled streptococcus protein G is not affected.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
A stabilizing and protecting agent for low-concentration enzyme marked streptococcus protein G is prepared from fish gelatin (0.1-0.5%), chicken egg albumin (0.1-0.5%), polyvinylpyrrolidone (0.5%), triethanolamine (0.5%), glycerin (0.2%), tween (0.02%), proclin (300) (0.1%), and buffer solution (0.02 mol/L) containing sodium chloride (0.2 mol/L) with pH of 7.2 + -0.2.
The invention further adopts the technical scheme that the fish gelatin stabilizing and protecting agent comprises the following raw materials of 0.3-0.5% of fish gelatin, 0.3-0.5% of chicken serum albumin, 0.5% of polyvinylpyrrolidone, 0.5% of triethanolamine, 0.2% of glycerol, 0.02% of tween 20 and 0.1% of Proclin300, wherein the percentages of the raw materials are W/V, namely the mass and volume percentage, the buffer solution used by the stabilizing and protecting agent is 0.02mol/L of tris-hydrochloric acid buffer solution containing 0.2mol/L of sodium chloride, and the pH value of the buffer solution is 7.2+/-0.2.
The invention further adopts the technical scheme that the fish gelatin stabilizing and protecting agent comprises the following raw materials of 0.5% of fish gelatin, 0.5% of chicken egg albumin, 0.5% of polyvinylpyrrolidone, 0.5% of triethanolamine, 0.2% of glycerol, 0.02% of tween 20 and 0.1% of Proclin300, wherein the weight percentage of the raw materials is W/V, namely the weight and volume percentage, the buffer solution used by the stabilizing and protecting agent is 0.02mol/L of tris-hydrochloric acid buffer solution containing 0.2mol/L of sodium chloride, and the pH value of the buffer solution is 7.2+/-0.2.
The specific proportion of polyvinylpyrrolidone, triethanolamine, glycerol, tween 20 and Proclin300 are adopted for synergistic compounding, so that the enzyme marked streptococcus protein G still maintains higher activity and stability under low concentration.
The fish gelatin and the chicken egg albumin are inert proteins, can replace common fetal bovine serum, bovine serum albumin and the like in immunological detection, can be used as a low-concentration protein supplementary protective agent, and can not react specifically with target protective proteins.
Polyvinylpyrrolidone is used as a nonionic polymer compound, can be used as a dispersing agent of a liquid preparation, and improves the stability of enzymes and G proteins in a liquid environment.
The triethanolamine is an antioxidant, can prevent the enzyme-labeled streptococcal protein G from oxidative degradation, and improves the stability of the enzyme-labeled streptococcal protein G.
The glycerol is used as polyhydroxy compound, can form hydrogen bond with the enzyme-labeled streptococcus protein G, and forms a water film around the enzyme-labeled streptococcus protein G, so that the hydrolytic denaturation of the enzyme-labeled streptococcus protein G is prevented, and the denaturant can be prevented from approaching the active center of the enzyme.
Tween 20 as a nonionic surfactant can act on hydrophobic groups on the surface of the enzyme-labeled streptococcal protein G, so that the risk of local aggregation and precipitation of the enzyme-labeled streptococcal protein G is reduced, and the adsorption loss of the enzyme-labeled streptococcal protein G in a container is reduced.
Proclin300 is used as a heterocyclic sterilization preservative, and can effectively inhibit microorganism breeding in an enzyme-labeled dilution protective solution system so as to prolong the service life of the preparation.
As a further technical scheme of the invention, the preparation steps of the tris-hydrochloric acid buffer solution are as follows:
s1, weighing tris (hydroxymethyl) aminomethane and sodium chloride in proper amount of pure water, and stirring for dissolution;
S2, adjusting the pH value to 7.2+/-0.2 by using hydrochloric acid, and supplementing purified water until the final concentration of the tris (hydroxymethyl) aminomethane is 0.02mol/L and the final concentration of sodium chloride is 0.2mol/L;
And S3, stirring and mixing uniformly, and filtering and sterilizing by using a 0.22 mu m filter membrane to obtain the tris-hydroxymethyl aminomethane-hydrochloride buffer solution.
The beneficial effects of the invention are as follows:
1. The structure and activity stability of the enzyme-labeled streptococcal protein G in a low-concentration liquid state can be maintained for a long time by adopting the combination of inert protein, a high-molecular polymer and a polyhydroxy compound according to a certain proportion.
2. The novel sterilization preservative inhibition system is adopted, so that the novel sterilization preservative inhibition system does not have biochemical reaction with the enzyme marked streptococcus protein G, can effectively prevent microorganism breeding, is safe and environment-friendly, and effectively prolongs the storage life.
3. The high affinity and broad spectrum of the enzyme-labeled streptococcal protein G are fully considered, the use of protective proteins such as fetal bovine serum, BSA, casein and the like which can react with the protein G specifically is avoided, and the inert protective proteins such as fish gelatin, chicken egg albumin and the like of a non-mammal system are replaced, so that the interference to the enzyme-labeled streptococcal protein G is avoided.
Drawings
FIG. 1 is a graph showing the trend of the detected OD 450 values of the enzyme-labeled streptococcal protein G stored at 37.+ -. 2 ℃ in application example 3 of a stable protectant for low-concentration enzyme-labeled streptococcal protein G according to the present invention;
FIG. 2 is a graph showing the change of OD 450 values of the enzyme-labeled streptococcal protein G stored at 2-8℃in application example 3 of a stable protectant of the enzyme-labeled streptococcal protein G at a low concentration according to the present invention.
Detailed Description
The invention is further described in connection with the following detailed description, in order to make the technical means, the creation characteristics, the achievement of the purpose and the effect of the invention easy to understand.
A stabilizing and protecting agent for low-concentration enzyme marked streptococcus protein G is prepared from fish gelatin (0.1-0.5%), chicken egg albumin (0.1-0.5%), polyvinylpyrrolidone (0.5%), triethanolamine (0.5%), glycerin (0.2%), tween (0.02%), proclin (300) (0.1%), and buffer solution (0.02 mol/L) containing sodium chloride (0.2 mol/L) with pH of 7.2 + -0.2.
In a preferred embodiment, the preparation steps of the tris-hcl buffer are:
s1, weighing tris (hydroxymethyl) aminomethane and sodium chloride in proper amount of pure water, and stirring for dissolution;
S2, adjusting the pH value to 7.2+/-0.2 by using hydrochloric acid, and supplementing purified water until the final concentration of the tris (hydroxymethyl) aminomethane is 0.02mol/L and the final concentration of sodium chloride is 0.2mol/L;
And S3, stirring and mixing uniformly, and filtering and sterilizing by using a 0.22 mu m filter membrane to obtain the tris-hydroxymethyl aminomethane-hydrochloride buffer solution.
Example 1
And (3) adding 0.3G of fish gelatin, 0.3G of chicken egg albumin, 0.02ml of Tween 20 and 0.1ml of Proclin300 into each 100ml of tris-hydrochloride buffer solution, sufficiently dissolving, and filtering and sterilizing by using a 0.22 mu m filter membrane to obtain the stable protective agent 1 (EDB 1) of the enzyme-labeled streptococcal protein G.
Example 2
And (3) adding 0.3G of fish gelatin, 0.3G of chicken egg albumin, 0.5G of polyvinylpyrrolidone, 0.2ml of glycerol, 0.02ml of Tween 20 and 0.1ml of Proclin300 into each 100ml of tris-hydrochloride buffer solution, and filtering and sterilizing by using a 0.22 mu m filter membrane after the components are fully dissolved to obtain the stable protective agent 2 (EDB 2) of the enzyme-labeled streptococcal protein G.
Example 3
And (3) adding 0.1G of fish gelatin, 0.1G of chicken egg albumin, 0.5G of polyvinylpyrrolidone, 0.2ml of glycerol, 0.02ml of Tween 20 and 0.1ml of Proclin300 into each 100ml of tris-hydrochloride buffer solution, filtering and sterilizing by using a 0.22 mu m filter membrane after the components are fully dissolved, thus obtaining the stable protective agent 3 (EDB 3) of the enzyme-labeled streptococcal protein G.
Example 4
And (3) adding 0.1G of fish gelatin, 0.5G of chicken egg albumin, 0.5G of polyvinylpyrrolidone, 0.2ml of glycerol, 0.02ml of Tween 20 and 0.1ml of Proclin300 into each 100ml of tris-hydrochloride buffer solution, and filtering and sterilizing by using a 0.22 mu m filter membrane after the components are fully dissolved to obtain the stable protective agent 4 (EDB 4) of the enzyme-labeled streptococcal protein G.
Example 5
0.5G of fish gelatin, 0.1G of chicken egg albumin, 0.5G of polyvinylpyrrolidone, 0.5G of triethanolamine, 0.2ml of glycerol, 0.02ml of Tween 20 and 0.1ml of Proclin300 are added into each 100ml of tris-hydrochloride buffer solution, and after complete dissolution, the stable protective agent 5 (EDB 5) of the enzyme marked streptococcal protein G is obtained by filtering and sterilizing with a 0.22 mu m filter membrane.
Example 6
0.5G of fish gelatin, 0.5G of chicken egg albumin, 0.5G of polyvinylpyrrolidone, 0.5G of triethanolamine, 0.2ml of glycerol, 0.02ml of Tween 20 and 0.1ml of Proclin300 are added into each 100ml of tris-hydrochloride buffer solution, and after complete dissolution, the stable protective agent 6 (EDB 6) of the enzyme marked streptococcal protein G is obtained by filtering and sterilizing with a 0.22 mu m filter membrane.
Comparative example 1
And (3) adding 0.6gBSA G polyvinylpyrrolidone, 0.2ml glycerol, 0.02ml Tween 20 and 0.1ml Proclin300 into each 100ml of tris-hydroxymethyl aminomethane-hydrochloride buffer solution, sufficiently dissolving, and filtering and sterilizing by using a 0.22 mu m filter membrane to obtain the stable protective agent (EDB) of the comparative enzyme marked streptococcal protein G.
The effect of the enzyme-labeled streptococcal protein G stabilizing protectant prepared in examples 1-6 was evaluated, and the following procedures were performed according to the application examples:
Application example 1
The enzyme-labeled streptococcal protein G was diluted 1:4000-fold to working concentration with the stabilizing protectants for the enzyme-labeled streptococcal protein G prepared in example 1-example 6 and comparative example 1, respectively.
And (3) placing the diluted enzyme marked streptococcus protein G in a 37 ℃ plus or minus 2 ℃ constant temperature and humidity box for 1 week and a2 ℃ to 8 ℃ refrigerator for 12 months respectively for preservation, and observing the change of physical properties and detecting the reduction amplitude of the absorbance value.
Application example 2
The absorbance of OD450 nm was sampled daily for 7 consecutive days to calculate the decrease in absorbance using the working concentration enzyme-labeled streptococcal protein G stored at 37.+ -. 2 ℃ in application example 1. The absorbance of the enzyme-labeled streptococcal protein G with the working concentration stored at 2-8 ℃ in application example 1 was sampled and detected at months 0, 6 and 12 to obtain OD450 nm, and the decrease of the absorbance was calculated.
The detection result shows that the enzyme-labeled G protein diluted by the stable protective agent of the enzyme-labeled streptococcal protein G is preserved for 7 days at 37+/-2 ℃ and for 12 months at 2-8 ℃, and the physical properties of the enzyme-labeled G protein are clear and transparent liquid without sediment and turbidity and change.
Application example 3
An ELISA plate coated with the E2 protein of the swine fever virus is adopted, positive serum and negative serum of the swine fever virus antibody with working concentrations are added, incubation is carried out for 45 minutes at 37 ℃, PBST is used for washing 4 times, then enzyme-labeled streptococcal protein G prepared in comparative example 1 and examples 1-6 is added, incubation is carried out for 45 minutes at 37 ℃, PBST is used for washing 4 times, substrate solution is added for color development, stop solution is added after 10 minutes, an enzyme-labeled instrument is used for reading, the light absorption value of OD450 nm is shown in tables 1 and 2, and the stability change trend is shown in figures 1 and 2.
As can be seen from Table 1 and FIG. 1, after 7 days of storage at 37.+ -. 2 ℃, the OD 450 value of comparative example 1 was reduced by 32.95%, and the OD 450 values of examples 1-6 were reduced by 14.05%, 8.06%, 14.85%, 11.85%, 11.23% and 4.98%, respectively, indicating that example 6 works best.
As can be seen from Table 2 and FIG. 2, the OD 450 value of comparative example 1 was 36.70% lower and the OD 450 values of examples 1-6 were 21.57%, 6.03%, 22.34%, 16.51%, 15.17% and 4.71% lower, respectively, after 12 months of storage at 2-8 ℃, indicating that example 6 works best.
The results show that the stable protective agent in the example 6 has the best protective effect on the enzyme-labeled streptococcus protein G, the enzyme-labeled streptococcus protein G diluted by the stable protective agent in the example 6 is preserved for 7 days at 37 ℃ plus or minus 2 ℃ and 12 months at 2 ℃ to 8 ℃ without obvious change of biological activity, and the change amplitude of the OD 450 value is less than 10 percent. The invention has excellent effect of preserving and stabilizing the enzyme marked streptococcus protein G.
TABLE 1 detection of enzyme-labeled streptococcal protein G at 37.+ -. 2 ℃ stored assay
TABLE 2 detection results of enzyme-labeled streptococcal protein G at 2℃to 8℃save
From the above description, it can be seen that the above embodiments of the present invention achieve the following technical effects that the structure and activity of the enzyme-labeled streptococcal protein G in a low concentration liquid state can be maintained for a long time by using the combination of the inert protein, the high molecular polymer and the polyhydroxy compound according to a certain proportion;
The novel sterilization preservative inhibition system is adopted, so that the novel sterilization preservative inhibition system does not have biochemical reaction with the enzyme marked streptococcus protein G, can effectively prevent microorganism breeding, is safe and environment-friendly, and effectively prolongs the storage life;
The high affinity and broad spectrum of the enzyme-labeled streptococcal protein G are fully considered, the use of protective proteins such as fetal bovine serum, BSA, casein and the like which can react with the protein G specifically is avoided, and the inert protective proteins such as fish gelatin, chicken egg albumin and the like of a non-mammal system are replaced, so that the interference to the enzyme-labeled streptococcal protein G is avoided.
It will be appreciated by persons skilled in the art that the foregoing discussion of any embodiment is merely exemplary and is not intended to imply that the scope of the invention (including the claims) is limited to these examples, that combinations of technical features in the foregoing embodiments or in different embodiments may be implemented in any order and that many other variations of the different aspects of the invention as described above may exist within the spirit of the invention, and that they are not provided in detail for clarity.
The present invention is intended to embrace all such alternatives, modifications and variances which fall within the broad scope of the appended claims. Therefore, any omission, modification, equivalent replacement, improvement, etc. of the present invention should be included in the scope of the present invention.
Claims (4)
1. A stabilizing and protecting agent for low-concentration enzyme marked streptococcus protein G is characterized by comprising the following raw materials of 0.1% -0.5% of fish gelatin, 0.1% -0.5% of chicken egg albumin, 0.5% of polyvinylpyrrolidone, 0.5% of triethanolamine, 0.2% of glycerol, 0.02% of tween 20 and 0.1% of Proclin300, wherein the percentages of the raw materials are W/V, namely the mass and volume percentage, the buffer solution used by the stabilizing and protecting agent is 0.02mol/L of tris-hydrochloric acid buffer solution containing 0.2mol/L of sodium chloride, and the pH value of the buffer solution is 7.2+/-0.2.
2. The stabilizing and protecting agent for the low-concentration enzyme-labeled streptococcus protein G according to claim 1, which is characterized by comprising the following raw materials of 0.3% -0.5% of fish gelatin, 0.3% -0.5% of chicken egg white albumin, 0.5% of polyvinylpyrrolidone, 0.5% of triethanolamine, 0.2% of glycerol, 0.02% of tween 20 and 0.1% of Proclin300, wherein the percentages of the raw materials are W/V, namely the mass and volume percentage, the buffer solution used for the stabilizing and protecting agent is 0.02mol/L of tris-hydrochloric acid buffer solution containing 0.2mol/L of sodium chloride, and the pH value of the buffer solution is 7.2+/-0.2.
3. The stabilizing and protecting agent for the low-concentration enzyme-labeled streptococcal protein G, according to claim 1, is characterized by comprising the following raw materials of 0.5% of fish gelatin, 0.5% of chicken egg albumin, 0.5% of polyvinylpyrrolidone, 0.5% of triethanolamine, 0.2% of glycerol, 0.02% of tween 20 and 0.1% of Proclin300, wherein the percentages of the raw materials are W/V, namely the mass and volume percentage, the buffer solution used by the stabilizing and protecting agent is 0.02mol/L of tris-hydrochloric acid buffer solution containing 0.2mol/L of sodium chloride, and the pH value of the buffer solution is 7.2+/-0.2.
4. The stable protectant for low-concentration enzyme-labeled streptococcal protein G according to claim 1, wherein the preparation process of the tris-hcl buffer comprises the steps of:
s1, weighing tris (hydroxymethyl) aminomethane and sodium chloride in proper amount of pure water, and stirring for dissolution;
S2, adjusting the pH value to 7.2+/-0.2 by using hydrochloric acid, and supplementing purified water until the final concentration of the tris (hydroxymethyl) aminomethane is 0.02mol/L and the final concentration of sodium chloride is 0.2mol/L;
And S3, stirring and mixing uniformly, and filtering and sterilizing by using a 0.22 mu m filter membrane to obtain the tris-hydroxymethyl aminomethane-hydrochloride buffer solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410496155.2A CN118388609B (en) | 2024-04-24 | 2024-04-24 | A stable protective agent for low-concentration enzyme-labeled streptococcal protein G |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410496155.2A CN118388609B (en) | 2024-04-24 | 2024-04-24 | A stable protective agent for low-concentration enzyme-labeled streptococcal protein G |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118388609A CN118388609A (en) | 2024-07-26 |
| CN118388609B true CN118388609B (en) | 2025-03-25 |
Family
ID=91998550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410496155.2A Active CN118388609B (en) | 2024-04-24 | 2024-04-24 | A stable protective agent for low-concentration enzyme-labeled streptococcal protein G |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118388609B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101995463A (en) * | 2009-08-14 | 2011-03-30 | 上海荣盛生物药业有限公司 | Composition for detecting rheumatoid arthritis immune antibody by dot immuno-gold filtration assay |
| AU2012201999A1 (en) * | 2004-05-10 | 2012-05-03 | Abgenomics Cooperatief U.A. | Antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000037648A1 (en) * | 1998-12-22 | 2000-06-29 | The University Of Tennessee Research Corporation | Protective antigen of group a streptococci (spa) |
| JP3950050B2 (en) * | 2000-11-01 | 2007-07-25 | 株式会社ガルファーマ | Cancer metastasis detection agent |
| CN115993460B (en) * | 2023-03-22 | 2023-06-02 | 珠海科域生物工程股份有限公司 | Alkaline phosphatase-labeled myoglobin antibody diluent and preparation method thereof |
| CN117092344B (en) * | 2023-07-19 | 2024-04-19 | 武汉睿奇生物工程有限公司 | A kit for detecting Staphylococcus aureus protein A and its application |
| CN117491651A (en) * | 2023-11-01 | 2024-02-02 | 首都医科大学宣武医院 | A quantitative detection kit, detection method and application of Tau complex bound to hemoglobin |
-
2024
- 2024-04-24 CN CN202410496155.2A patent/CN118388609B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012201999A1 (en) * | 2004-05-10 | 2012-05-03 | Abgenomics Cooperatief U.A. | Antibodies |
| CN101995463A (en) * | 2009-08-14 | 2011-03-30 | 上海荣盛生物药业有限公司 | Composition for detecting rheumatoid arthritis immune antibody by dot immuno-gold filtration assay |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118388609A (en) | 2024-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10527616B2 (en) | Method for detecting Staphylococcus contained in milk | |
| KR101606878B1 (en) | Method of stabilizing hem protein and storage solution therefor | |
| US7955792B2 (en) | Diluent for norovirus or sapovirus specimen and method for detecting virus | |
| CN113717282A (en) | Antibody diluent | |
| CN118388609B (en) | A stable protective agent for low-concentration enzyme-labeled streptococcal protein G | |
| CN107043762A (en) | A kind of preserving stabilizer and its store method for improving horseradish peroxidase storage stability | |
| JP4261665B2 (en) | Method for stabilizing human hemoglobin in solution and stabilizing solution | |
| JP4039590B2 (en) | Stabilization of hemoglobin samples | |
| CN113238038B (en) | Antibody diluent for immunohistochemical detection and preparation method and application thereof | |
| CN117054662A (en) | KIM-1 chemiluminescence kit | |
| CN107602695B (en) | Fluorescent antibody preservation solution, kit and application thereof, and fluorescent antibody preservation method | |
| JPH07229902A (en) | Method for stabilizing hemoglobin | |
| CN109307720B (en) | Composition, composite calibrator and application of composite calibrator | |
| CN118330207B (en) | Fixing agent for improving fluorescent background in fixed cell immunofluorescence method and method for fixing cells by using fixing agent | |
| CN118937682B (en) | Kit for heparin binding protein detection and preparation method thereof | |
| Benveniste et al. | Effects of ionic concentration and pH upon the state of aggregation of Neurospora mitochondrial malate dehydrogenase | |
| US4956299A (en) | Complement stabilization | |
| CN118032448A (en) | Preparation and application of normal-temperature preservation solution for animal serum samples | |
| CN115015559A (en) | A C-reactive protein detection kit | |
| West | Heparin inhibition of human neutrophil and eosinophil-enriched leukocyte acid β-glycerophosphatase | |
| CN116047072A (en) | Sialidase NEU1 chemiluminescent detection kit and method for detecting sialidase NEU1 | |
| CN117706076A (en) | Use of ectoine as protein stabilizer | |
| CN119510741A (en) | Anti-Mullerian hormone quality control product and its preparation method and application | |
| CN114410390A (en) | Cleaning solution for chemiluminescence reaction system and preparation method thereof | |
| CN118130799A (en) | Hepatitis C virus antibody detection kit and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |